52U Stock Overview
Engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Hyloris Pharmaceuticals SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €6.22 |
| 52 Week High | €13.35 |
| 52 Week Low | €3.22 |
| Beta | 0.46 |
| 1 Month Change | 11.47% |
| 3 Month Change | 9.12% |
| 1 Year Change | -50.24% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 52U | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 18.7% | 1.4% | 0.5% |
| 1Y | -50.2% | -16.3% | 7.2% |
Return vs Industry: 52U underperformed the German Pharmaceuticals industry which returned -17% over the past year.
Return vs Market: 52U underperformed the German Market which returned 7% over the past year.
Price Volatility
| 52U volatility | |
|---|---|
| 52U Average Weekly Movement | 15.0% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 52U's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 52U's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 41 | Stijn Van Rompay | hyloris.com |
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases.
Hyloris Pharmaceuticals SA Fundamentals Summary
| 52U fundamental statistics | |
|---|---|
| Market cap | €168.00m |
| Earnings (TTM) | -€13.24m |
| Revenue (TTM) | €6.94m |
24.2x
P/S Ratio-12.7x
P/E RatioIs 52U overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 52U income statement (TTM) | |
|---|---|
| Revenue | €6.94m |
| Cost of Revenue | €155.00k |
| Gross Profit | €6.79m |
| Other Expenses | €20.03m |
| Earnings | -€13.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 20, 2025
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 97.77% |
| Net Profit Margin | -190.79% |
| Debt/Equity Ratio | 0.3% |
How did 52U perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 04:21 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hyloris Pharmaceuticals SA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beatrice Allen | Berenberg |
| Laura Roba | Degroof Petercam |
| David Seynnaeve | Degroof Petercam |